The proband provided informed consent and DNA was obtained from whole blood in 2005 under a protocol approved by the University of Western Ontario Ethics Review Board (#07920E). LipidSeq, 5 a targeted NGS and bioinformatics platform, was used to assess for pathologic mutations in known MODY-associated genes, and none were detected. Her original NGS output data was recently reanalyzed 13 years after the original testing was completed using the VS-CNV caller function in VarSeq v1.4.3 (Golden Helix, Bozeman, Montana), a technique that takes advantage of depth-of-coverage (DOC) information provided from raw NGS data to predict the presence of CNVs. A whole-gene deletion of HNF4A (MODY1) was detected ( Figure 1B) . The CNV average ratio for this deletion was 0.531123 with a Z-score of −6.6691 (significance threshold −5) for the targeted NGS data and an average ratio of 0.577031 with a Zscore of −2.94078 (significance threshold −2) and a P-value of <1 × 10 −30 for confirmatory whole exome sequencing (WES). This deletion has not been previously reported and would be expected to be causal for MODY.
Bioinformatic detection of copy number variation in HNF4A causing maturity onset diabetes of the young To the Editor:
Maturity onset diabetes of the young (MODY) 1,2 is currently under-recognized clinically, 3 and may also be under-recognized by molecular genetic analysis. 1 Genetic testing for MODY is presently accomplished primarily using next generation sequencing (NGS) techniques. 1, 2, 4 However, these techniques are historically unable to detect copy number variations (CNVs), defined as large-scale deletions or duplications in genomic DNA. We report here on a largescale heterozygous CNV in HNF4A causing MODY in an individual who initially tested negative for mutations by DNA sequencing alone.
The proband carrying this mutation was a Caucasian female, diagnosed with diabetes at age 16. She has a normal body mass index with negative diabetes-associated autoantibodies and a significant family history of diabetes. She was managed effectively with a sulphonylurea for several years, with improvement in HbA1c from 7.5% to 5.6% compared to multiple daily injections of insulin. Sulphonylurea therapy eventually became ineffective and insulin was re-initiated. 
